Table 2 Median total doses for dose escalation of PET-positive local recurrence and pelvic lymph nodes and median total dose for oligometastatic bone lesions
From: A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer
Median total dose in EQD2(1.5 Gy) [Gy] | Median single dose [Gy] | RT technique | |
|---|---|---|---|
PET-positive local recurrence | 70.00 (range: 56.89–85.71) | 2.00 (range: 1.80–4.30) | SQB: 24.4% (21/86) |
SIB: 66.3% (57/86) | |||
No boost: 2.3% (2/86) | |||
Other: 7.0% (6/86), one with LDR-brachytherapy with 108 Gy | |||
PET-positive pelvic LNs | 62.00 (range: 52.61–80.00) | 2.00 (range: 1.80–2.60) | SQB: 19.8% (13/84) |
SIB: 75.6% (65/84) | |||
No boost: 3.5% (3/86) | |||
Other: 1.2% (1/86) with a SBRT boost | |||
Oligometastatic bone lesions | 64.64 (range: 31.43–197.14) | 5.00 (range: 1.80–20.00) | CRT: 51.4% (56/109) |
SBRT: 43.1% (47/109) | |||
No RT: 5.5% (6/109) |